PARADIGM BIOPHARMACEUTICALS LIMITED..
ASX:PARPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 81.8% of what they think they own, once every option and right converts.
Runway under 2 quarters; share count grew 79% in 24 months; 5 cash raises in 24 months
PARADIGM BIOPHARMACEUTICALS LIMITED.. ordinary shares increased by 78.7% between September 2024 and September 2026, reaching 626M. In the past 24 months, the company completed five capital raises totaling A$55.7M, with the most recent being a A$21.4M placement and share purchase plan in April 2026. There are potential new shares of 140M on issue from options, representing 22.3% of current shares, none of which are in the money; the nearest expiry date for these options is December 2026. As of June 2026, the company held A$3.7M in cash, which provided cover for approximately 0.3 quarters of operations. No new proposed issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 11 Sept 2026 | 2A · quoted issue | PAR : ORDINARY FULLY PAID | 625.7M | Appendix 2A |
| 11 Sept 2026 | 3G · unquoted | ORDINARY FULLY PAID | 606.8M | Appendix 3G |
| 25 Aug 2026 | 2A · quoted issue | PAR : ORDINARY FULLY PAID | 606.8M | Appendix 2A |
| 30 July 2026 | 2A · quoted issue | PAR : ORDINARY FULLY PAID | 599.2M | Appendix 2A |
| 26 July 2026 | 3H · cancellation | PAR : ORDINARY FULLY PAID | 594.0M | Appendix 3H |
Capital raises
5 cash raises in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered120.2M · 19.2% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 117.1M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered11.1M · 1.8% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
- Converts on terms8.3M · 1.3% of sharesConvertibles with no exercise price — they convert on their own terms, so they are shares in all but name.
Exercise price on record: 3.2M priced, 136.5M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
An exercise price is on record for only 2.3% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.28 today. No more priced supply until 3× today’s price, which takes it to 3.0M (0.5% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 136.5M (97.7% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| PAROB | Options | Price-triggered | — | 1 Dec 2026 | 117.1M | Filing |
| PARAAE | Options | Price-triggered | $0.65 | 30 June 2027 | 3.0M | Filing |
| PARAR | Options | Price-triggered | $1.00 | 11 Feb 2028 | 151k | Filing |
| PARAAD | Notes | Converts on terms | — | — | 8.3M | Filing |
| PARAAC | Performance rights | Condition-triggered | — | — | 11.1M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 29 June 2026 | Paul Rennie | Sell incentive | — | — | — | — | 3Y notice |
| 18 June 2026 | Matthew Fry | Other entitlement/SPP | 1.6M | 176k | — | — | 3Y notice |
| 18 June 2026 | Paul Rennie | Other entitlement/SPP | — | 176k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.